Search

Byline: NJBIZ STAFF Merck is one of the most prominent research-intensive biopharmaceutical companies in the world. Founded more than a century ago, Rahway-based Merck provides innovative health solutions that advance [...]

NEW YORK: Qure.ai Technologies Limited has issued the following news release: Qure.ai, a global healthcare AI innovator, has announced the completion of a $65 million Series D funding round. The [...]

London: Hipgnosis Song Management Ltd has issued the following press release: Hipgnosis Song Management Ltd - London-based music investment company - Says Merck Mercuriadis, founder and chair intends to step [...]

London: Association of Investment Companies has issued the following press release: Merck Mercuriadis, chairman and founder of Hipgnosis Song Management (HSM), the manager of Hipgnosis Songs Fund (SONG) has given [...]

Byline: MUSIC LICENSING Daniel O'Boyle THE extraordinary six-year saga of music rights business Hipgnosis Songs Fund as a publicly quoted company is set to end after it today agreed a [...]

Byline: MUSIC LICENSING Daniel O'Boyle MUSIC industry veteran Merck Mercuriadis is taking a step back from his direct involvement with managing royalties, in a move that may be a step [...]

Byline: Jasper Jolly Hipgnosis Songs Fund, which owns the streaming rights to artists ranging from Beyoncé to Neil Young, has sold a chunk of its song rights at a steep [...]

The company's shareholders on Thursday rejected a $440 million divestment plan and voted against maintaining its current structure. The future of Hipgnosis Songs Fund, the British company that helped kick [...]

The music publishing industry experienced a significant shift with the emergence of the various Hipgnosis funds, a related group of companies that has been making headlines for its ambitious catalog [...]

Merck, a leading science and technology company, has completed the second phase of its new EUR 29 M Biologics Testing Center in China adding 1500 sq m to the lab, which opened in 2022. These are the first biosafety laboratories for Merck in this market, enabling clients to locally access a broad range of testing services for cell line characterization and lot release from pre-clinical development to commercialization. The first phase of investment provides testing services for viral clearance studies, a critical step in drug development. The second phase adds capabilities for cell line characterization that support biopharma customers to ensure the safety, purity, and identity of their cell banks. The testing centre also offers cGMP-compliant lot release testing for unprocessed and purified bulk harvest to meet requirements for biologics entering preclinical and clinical studies, as well as licensed biologics. With the completion of phase two of the facility, Merck now offers a broad range of biosafety testing services for monoclonal antibodies, other recombinant proteins, and cell and gene therapies. The Shanghai facility joins Merck's global biosafety testing network with sites in Singapore; Stirling and Glasgow, UK; and Rockville, MD, USA, and shares the same global expertise, standards, and quality systems. Merck's BioReliance testing services portfolio offers clients leading innovation to ensure the safety and quality of the biopharma industry's supply chain. As a leader in the biosafety testing industry, Merck has more than 1000 clients globally with industry-leading portfolio breadth for major modalities (mAbs, ADCs, CGT, mRNA, and vaccines). Original source: Sigma-Aldrich, website: http://www.sigmaaldrich.com/, Copyright Sigma-Aldrich Co LLC 2023., investment; research and development; cell therapies; gene therapies; monoclonal antibodies; therapeutic proteins; [...]

Quakertown, Nov. 8 -- Synergis Software, a global leader in engineering document management and workflow solutions, today announced they will participate in a collaborative, live panel with leaders from Merck, [...]

Leaders from Merck, Synergis Software, and IPS-Integrated Project Services present Merck's implementation of Synergis Adept to achieve validation for cGMP requirements QUAKERTOWN, Pa. -- Synergis Software, a global leader in [...]

2023 MAR 15 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Oncology - Pancreatic Cancer have been published. According to news reporting [...]

Byline: Eric Stirgus eric.stirgus@ajc.com and Ariel CORONAVIRUS Georgia State University researchers believe theyve taken a step forward in helping to develop an oral drug to treat COVID-19. A new front [...]

DARMSTADT: Merck has issued the following news release: Merck, a leading science and technology company, announced that its Life Science business sector has doubled its high-potent active pharmaceutical ingredients (HPAPI) [...]

Merck, a leading science and technology company, announced that its Life Science business sector has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, near Madison, WI, US. This new EUR 59 M, 70,000 sq ft facility, officially opened on 23 Jun 2022, brings 50 new jobs to the area. Cancer is the second leading cause of death worldwide. HPAPIs are a critical element of targeted therapies due to their extremely effective cell-killing abilities at low doses, resulting in reduced side effects for patients. They are used in novel cancer therapies, including antibody drug conjugates (ADCs), which are changing the landscape of cancer treatments. Merck has been developing multi-step, complex, and highly potent compounds for more than 30 years and continues to be an industry leader in the development and manufacture of these components. HPAPIs require specialized handling and manufacturing facilities that protect the safety of employees and their environment. Many potential life-saving treatments never make it to market in part due to the specialized handling requirements. Merck's Verona, WI site was the second facility in the world to be SafeBridge-certified and the company continues to meet these rigorous safety and containment requirements necessary to this day. In fact, this expansion positions Merck as one of the largest single-digit nanogram occupational exposure limit (OEL) CDMO providers in the world. HPAPIs are measured with the most potent registering less than 10 nanograms/cu m. Single-digit nanogram HPAPIs require highly specialized handling, which is reflected by the OEL designation. In addition to HPAPI production, Merck also has extensive experience developing and manufacturing ADCs. Being the first CDMO to manufacture commercially approved ADC drugs in North America, the company recently launched new technologies to advance ADC therapies. Its unique ChetoSensar technology gives new promise to ADCs by alleviating solubility challenges, and Merck's new DOLCORE platform significantly reduces development and manufacturing time required, increasing speed-to-market by up to a year, ultimately getting needed therapies to patients quicker. With more than 30 years of CDMO experience in the development and manufacturing of HPAPIs, linkers and mAbs, Merck offers significant expertise in both clinical and commercial manufacturing. The company also has extensive CDMO experience in viral vector, lipids, LNP and mRNA manufacturing - from pre-clinical to commercial - helping to streamline steps of drug development and production with a single, highly experienced partner. Additionally, BioReliance contract testing services are integrated into the overall Services offering to further streamline the development path. Original source: Sigma-Aldrich, website: http://www.sigmaaldrich.com/, Copyright Sigma-Aldrich Co LLC 2022., contract; employment; investment; new technology or process; plant capacity; plant restructuring; pharmaceutical ingredients; therapeutic antibodies; BioReliance; [...]

Mid-sized companies & smaller biotechs join big names including Merck and Pfizer to manage data, content & processes via the single, cloud-based, SaaS platform & information lake. Japan, the world's [...]

Merck Animal Health and Oval Park Capital continue strong support as valued investors MORRISVILLE, N.C. -- TARGAN (formerly Applied LifeSciences & Systems (ALSS)) announced today it has secured $35 million [...]

2023 JAN 27 (NewsRx) -- By a News Reporter-Staff News Editor at Science Letter -- Researchers detail new data in social science. According to news reporting out of the Universitas [...]

Rome: Association European Businesses has issued the following press release: the AEB Legal Committee and the Legal & Taxation Sub-Committee of the AEB North-Western Regional Committee held a joint event [...]

MOSCOW, Russia -- The following information was released by the Association of European Businesses (AEB): On April 28 , the AEB Legal Committee and the Legal and Taxation Sub-Committee of [...]

2022 OCT 21 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in urothelial cancer. According to news originating from Seattle, [...]

Brooklyn, NY, Nov 09, 2021 (GLOBE NEWSWIRE via COMTEX) -- Laurie Halloran, a pioneer in life sciences, has joined Datacubed Health's Board of Directors. Laurie is President and CEO of [...]

London: Hipgnosis Songs Fund Ltd has issued the following press release: Hipgnosis Songs Fund Ltd said Tuesday its investment manager, Hipgnosis Song Management Ltd, has signed a partnership with US [...]